Ventripoint Announces Appointment of Justin Leushner as CEO
and Changes to the Board of Directors
Toronto, Ontario, November 4, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce it has appointed Justin Leushner as CEO of Ventripoint. Dr. George Adams has resigned as CEO and has been elected as Chairman of the Board of Directors of Ventripoint.
Mr. Leushner’s appointment is a reflection of the Company’s current state: ready for commercial success. Ventripoint is poised for major growth and Justin’s unique leadership experience in life sciences and biotechnology will help ensure the Company’s future success. There is enormous opportunity for Ventripoint and all at the Company look forward to having Mr. Leushner at the helm.
“With regulatory approvals received for the VMS+ 3.0 in Canada, Europe and the USA, I have accomplished my goal as CEO of leading the team to create the best cardiac analysis device in the market. It was very rewarding to hear one cardiologist at a leading hospital say he could get an MRI done in 20 minutes but would rather use the VMS+ 3.0. Another one said, “This is like a microwave oven – once you use it, you cannot imagine not having one.” I would like to thank our shareholders for your long-term support and ask your support for Justin as he leads the next phase of commercialization and value creation,” stated Dr. Adams, Chairman of the Board.
“Those of us who have worked for so many years with George know that the shareholders, executive team and employees owe him a huge debt of gratitude for his extraordinary efforts on behalf of the Company. All of us at Ventripoint wish him well and thank him for his leadership, guidance, inspiration and support as CEO,” said Don Segal, Ventripoint Director.
“We would like to thank Dr. George Adams for his dedication to the Ventripoint technology as CEO for the past 9 years. I am excited to have the opportunity to lead Ventripoint in this new chapter. Working with the strong management and clinical team over the past few months, it is clear that the Company is now ready to achieve its full potential as we begin selling our new system to hospitals and cardiac centers worldwide,” commented Mr. Leushner, Ventripoint CEO.
Mr. Leushner is a highly regarded leader in the medical device industry, with a proven track record of building great businesses and creating shareholder value. In 2004, Mr. Leushner co-founded Sernova Corp., currently traded on the Toronto Stock Exchange, and most recently was the CEO of the Centre for Imaging Technology Commercialization (CIMTEC). An MBA graduate of the University of Western Ontario’s Ivey School of Business, Justin also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.
Mr. Leushner has also been appointed a Director of the Company and Mr. Danny Dalla-Longa has stepped down as a Director. The Company wishes to thank Mr. Dalla-Longa for his valuable advice and service to the Company for more than a decade.
“Best practices require Board renewal and as the longest standing member of the Board of Directors, it is time for me to allow a new Director to be appointed,” commented Mr. Dalla-Longa. “I have enjoyed working with the other Directors and I know the Company has a bright future.”
The Board of Directors of the Company has issued Mr. Leushner 500,000 option grants each at an exercise price of $0.10 for a term of 5 years, vesting quarterly over 3 years.
About Ventripoint Diagnostics Ltd.
Ventripoint’s VMS+ 3.0 system connects to standard echo machines, the most widely used cardiac imaging technology globally. The system uses a proprietary Knowledge Based Reconstruction (KBR) technology to create 3D images of the heart and calculates volumes & ejection fraction with accuracy equivalent to MRI. The system provides consistent, reproducible results for all four chambers of the heart including the difficult to measure RV for adult and pediatric patients.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release